Document is current

Article History

Received: 26 May 2024

Accepted: 19 August 2024

First Online: 29 October 2024

Acknowledgements

: The authors would like to acknowledge the contributions of the(sugar)science, a type 1 diabetes research advocacy organisation, for initiating, organising and hosting the consortium activities. All screen grabs of the iReceptor Gateway are provided with the permission of the iReceptor project.Type 1 Diabetes AIRR Consortium members: Erin Baschal [Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO 80045, USA], Karen Cerosaletti [Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA], Lorissa Corrie [iReceptor Genomic Services, Summerland, BC, Canada], Iria Gomez-Tourino [Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Santiago de Compostela, Spain], Lauren Higdon [Diabetes Center, University of California San Francisco, San Francisco, CA, USA], Sally C. Kent [Diabetes Center of Excellence, Department of Medicine, University of Massachusetts Medical Chan School, Worcester, MA, USA], Peter Linsley [Benaroya Research Institute, Seattle, WA 98101, USA], Maki Nakayama [Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO 80045, USA], Kira Neller [iReceptor Genomic Services, Summerland, BC, Canada], William E. Ruff [Repertoire Immune Medicines, Cambridge, MA 02139, USA], Luc Teyton [Department of Immunology and Microbiology, Scripps Research, La Jolla, CA 92037, USA]

: All data in Table are available from Data from Fig. are available at

: SJH is funded by the Diabetes Research and Wellness Foundation Professor David Matthews Non-Clinical Research Fellowship, The Leona M. and Harry B. Helmsley Charitable Trust by grant #2101-04969, and this work was supported on behalf of the “Steve Morgan Foundation Type 1 Diabetes Grand Challenge” by Breakthrough T1D UK, formerly JDRF and SMF (grant numbers 2-SRA-2024-1474-M-N and 2-SRA-2024-1473-M-N). This work was also funded by NIH grants R01 DK131070 (RHB), DK108868 (AWM), DK032083 (AWM), DK099317 (AWM), U24 AI177622 (FB, BC) and U01-DK112217 (ETLP). TMB is funded by NIH P01 AI042288 and AWM and TMB by The Leona M. and Harry B. Helmsley Charitable Trust by grant #2301-06562.

: TMB has consulted for Repertoire Immune Medicines and both TMB and AWM have received in-kind sequencing support by Adaptive Biotech. BC and FB are both researchers on the iReceptor team at Simon Fraser University and are partners in iReceptor Genomic Services. The other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

: SJH, RHB, ALP, ETLP, MW, FB, AWM and TMB were responsible for conceptualisation and design of the work. BC was responsible for data curation: MW provided project administration for the Type 1 Diabetes AIRR Consortium. MW, SJH, RHB and BC wrote the original draft. All authors reviewed and edited the original draft and approved the final manuscript for publication. TMB and AWM are guarantors of this work